NASDAQ:DTIL

Precision Biosciences Stock News

Healthcare > Biotechnology

Buy DTIL

*Your capital is at risk

$6.04

-0.280 (-4.43%)

At Close: Jun 03, 2026

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

07:01am, Thursday, 07'th Aug 2025

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

07:01am, Wednesday, 06'th Aug 2025

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

07:01am, Monday, 04'th Aug 2025

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

07:01am, Wednesday, 23'rd Jul 2025

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

07:01am, Wednesday, 16'th Jul 2025

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

07:01am, Wednesday, 25'th Jun 2025

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

09:16am, Thursday, 15'th May 2025

Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago.

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

07:01am, Thursday, 15'th May 2025

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

04:30pm, Wednesday, 14'th May 2025

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

07:01am, Thursday, 08'th May 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

07:01am, Wednesday, 07'th May 2025

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

07:01am, Thursday, 01'st May 2025

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

07:00am, Tuesday, 29'th Apr 2025

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

09:55am, Wednesday, 16'th Apr 2025

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

07:01am, Tuesday, 15'th Apr 2025

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by